| Name | Title | Contact Details |
|---|
The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Straumann, Neodent, Medentika, ClearCorrect, Dental Wings, and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, biomaterials and digital solutions for use in tooth replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs approx. 6000 people worldwide and its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.
Quincy Lab is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synca Marketing Inc is a Le Gardeur, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Exo is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications. Exo is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world.
Our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. The pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. The team is complemented by world-class medical advisors. Our products have been organically conceived, researched and developed by the Company and all manufacturing activities are conducted to ensure compliance with the U.S. Food and Drug Administration (FDA) per the requirements of 21 CFR 820, as well as ISO 13485. Femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the U.S. Food and Drug Administration (FDA), European Union, Canada, and Japan with other select countries in process. Making a difference in the lives of women one product at a time is a great privilege and serves to drive the Company`s mission.